AI Article Synopsis
- Breast cancer is the leading cause of cancer deaths among women, particularly the aggressive triple-negative subtype that has a poor prognosis and relies heavily on chemotherapy, which often doesn’t extend survival.
- A notable case is presented of a patient with metastatic triple-negative breast cancer who experienced a significant and prolonged tumor response and survival after receiving pembrolizumab, an immunotherapy agent.
- While immunotherapy is showing potential for treating some breast cancer cases, current studies indicate limited effectiveness when used alone, and there is a need for better biomarkers to identify patients who could truly benefit from such treatments.
Article Abstract
Introduction: Breast cancer is the first cause of cancer death in women. The triple-negative subtype is associated with aggressive behavior and poor prognosis. Chemotherapy is the main therapeutic option available for these patients, but it is usually associated with short overall survival.
Case Presentation: We report the case of a patient diagnosed with metastatic triple-negative breast cancer with an impressive long-lasting tumor response and long-term survival after pembrolizumab monotherapy.
Conclusion: Immunotherapy is emerging as a promising treatment for some breast cancer patients. Nevertheless, monotherapy studies have shown a very limited activity. Nowadays, there is no good predictor biomarker. Further investigations are needed to identify the subgroup of patients who can benefit from checkpoint inhibitor treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490656 | PMC |
| http://dx.doi.org/10.1159/000503849 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!